Zelda Therapeutics to outline cannabinoid-based strategy at Proactive CEO Sessions

471

Zelda Therapeutics Ltd ( ASX:ZLD ) is developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions, with a focus on cancer therapies. The company is undertaking: • A human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

Ga naar Bron